976 results on '"Nadal, E."'
Search Results
152. Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: Initial results from the ALK+ cohort
153. MA23.02 CDK4/6 Inhibitors Show Antitumor Effects in Preclinical Models of Malignant Pleural Mesothelioma
154. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
155. P1.01-54 Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome
156. What do cancer patients know about their immunotherapy treatment?
157. P1.18-03 How to Predict High Grade Radiation Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Thoracic Radiotherapy
158. P1.01-111 ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
159. P2.13-04 Molecular Nodal Restaging Based on Embryonic Markers Expression Adds No Relevant Clinical Information in Resected Lung Cancer
160. MA13.03 Retrospective Study of Intrathecal Therapy for Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Carcinomatosis
161. P2.03-03 Landscape of Gene Fusions in Lung Adenocarcinoma Patients with Minimal Cigarette Exposure Identified on Malignant Pleural Effusions
162. Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients
163. OA13.05 NADIM Study: Updated Clinical Research and Outcomes
164. MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy
165. P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
166. P2.04-10 Biomarkers of Pathological Response on Neo-Adjuvant Chemo-Immunotherapy Treatment for Resectable Stage IIIA NSCLC Patients
167. Oral Propranolol Decreases Intestinal Permeability in Patients With Cirrhosis: Another Protective Mechanism Against Bleeding?
168. Application of the Cartesian Grid Finite Element Method to image-based bone remodelling process
169. Realtime Data from Europe ETOP / ESTS Database
170. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial
171. ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases
172. Preliminary results from a prospective study of germline alterations in early onset lung cancer patients (EOLUNG study)
173. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
174. Somatic Genome Alterations in Lung Cancer Patients Diagnosed with Li Fraumeni Syndrome
175. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
176. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose
177. MA16.04 Circulating Tumor DNA Quantification by NGS Should Be Adapted to the Methodology Used.
178. Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies
179. CD4+CD25+ regulatory T-cells favours leukaemia relapse after allogeneic stem cell transplantation
180. Secondary malignancies in recipients of allogeneic stem cell transplantation for CML in chronic phase using HLA-identical sibling or HLA-compatible unrelated donors
181. The combination of sRANKL/osteoprotegerin ratio, beta2-microglobulin and CRP predicts survival in patients with multiple myeloma post autologous stem cell transplantation
182. Smoldering multiple myeloma: natural history and recognition of an evolving type
183. P10.04 Incidence and characteristics of neurological adverse events secondary to immunotherapy with checkpoint inhibitors
184. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial
185. Prédiction épigénétique du bénéfice clinique avec les anti-PD-1 dans le traitement des cancers du poumon non à petites cellules avancées : une étude internationale multicentrique rétrospective
186. Estimating the Relative Stiffness between a Hepatic Lesion and the Liver Parenchyma through Biomechanical Simulations of the Breathing Process
187. Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
188. P1.01-68 Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
189. P1.13-29 Overall Response Rate of Nintedanib and Docetaxel in Combination with the Nutraceutical Use of Silibinin in Advanced NSCLC
190. OA01.05 Phase II Study of Neo-Adjuvant Chemo/Immunotherapy for Resectable Stages IIIA Non-Small Cell Lung Cancer- Nadim Study-SLCG
191. Analysis of spectinomycin by liquid chromatography with pulsed electrochemical detection
192. Thromboelastographic evaluation of hemostatic balance in cirrhotic patients with infection
193. Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
194. P05.21 T1-flair to T1-gadolinium MRI ratio as a predictive value of treatment response in non-small-cell lung cancer (NSCLC) patients affected by multiple brain metastases
195. PO-019 PTPN11 is a therapeutic target in KRAS mutant lung cancer
196. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients
197. PGD Variational vademecum for robot motion planning. A dynamic obstacle case
198. 2O MET activation in lung cancer up-regulates PD-L1 expression independently of JAK-STAT pathway, promoting an immunosuppressive phenotype
199. Étude randomisée de phase 1B/3 sur l’erlotinib + le ramucirumab dans les CBNPC de stade IV non traité présentant une mutation de l’EGFR : résultats de la phase 1B
200. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.